Ling Wei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ling Wei has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ming Yang
Department of Nephrology, The Second Xiangya Hospital of Central South University, 139 Renmin middle road, Changsha, Hunan, 410011, China; Hunan Key Laboratory of Kidney Disease and Blood Purification, 139 Renmin middle road, Changsha, Hunan, 410011, China
3 shared publications - Chenrui Li
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
2 shared publications - Lin Sun
Department of Nephrology, The Second Xiangya Hospital of Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, Changsha, China
2 shared publications - Lingfeng Zeng
Carol & Richard Yu Peritoneal Dialysis Research Centre, Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong, China
2 shared publications - Na Jiang
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
2 shared publications - Peng Gao
Department of Nephrology, The Second Xiangya Hospital Central South University, Hunan Key Laboratory of Kidney Disease and Blood Purification, No. 139 Renmin Middle Road, Changsha, Hunan,China
2 shared publications
Latest Publications
- 23 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1031
S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis
- 23 July 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1031
S14G-humanin (HNG) ameliorates diabetic nephropathy tubular injury by inhibiting Z-DNA/ZBP1-mediated necroptosis
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (14) , 2717-2728
Mitophagy: A Novel Therapeutic Target for Treating DN
Diabetic nephropathy (DN) is a common microvascular complication of diabetes and one of the leading causes of end-stage renal disease. Tubular damage is an early change and characteristic of DN, and mitochondrial dysfunction plays an important role in the development of DN. Therefore, the timely removal of damaged mitochondria in tubular cells is an effective treatment strategy for DN. Mitophagy is a type of selective autophagy that ensures the timely elimination of damaged mitochondria to protect cells from oxidative stress. In this review, we summarize our understanding of mitochondrial dysfunction and dynamic disorders in tubular cells in DN and the molecular mechanism of mitophagy. Finally, the role of mitophagy in DN and its feasibility as a therapeutic target for DN are discussed.
- 1 April 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (14) , 2717-2728
Mitophagy: A Novel Therapeutic Target for Treating DN
Diabetic nephropathy (DN) is a common microvascular complication of diabetes and one of the leading causes of end-stage renal disease. Tubular damage is an early change and characteristic of DN, and mitochondrial dysfunction plays an important role in the development of DN. Therefore, the timely removal of damaged mitochondria in tubular cells is an effective treatment strategy for DN. Mitophagy is a type of selective autophagy that ensures the timely elimination of damaged mitochondria to protect cells from oxidative stress. In this review, we summarize our understanding of mitochondrial dysfunction and dynamic disorders in tubular cells in DN and the molecular mechanism of mitophagy. Finally, the role of mitophagy in DN and its feasibility as a therapeutic target for DN are discussed.
- Open Access
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Aristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.
- 24 July 2020
- Published by Wiley in The FASEB Journal
- Vol. 34 (9) , 12599-12614
Open AccessAristolochic acid induces renal fibrosis by arresting proximal tubular cells in G2/M phase mediated by HIF‐1α
Renal tubulointerstitial fibrosis (TIF) is a common pathological feature of aristolochic acid (AA) nephropathy (AAN). G2/M arrest of proximal tubular cells (PTCs) is implicated in renal fibrosis of AAN, but the upstream regulatory molecule remains unknown. Hypoxia inducible factor‐1α (HIF‐1α) promotes renal fibrosis in kidney disease, but the role of HIF‐1α in AAN is unclear. Evidence shows that HIF‐1α and p21, a known inducer of cellular G2/M arrest, are closely related to each other. To investigate the role of HIF‐1α in renal fibrosis of AAN and its effects on p21 expression and PTCs G2/M arrest, mice with HIF‐1α gene knockout PTCs (PT‐HIF‐1α‐KO) were generated, and AAN was induced by AA. In vitro tests were conducted on the human PTCs line HK‐2 and primary mouse PTCs. HIF‐1α and p21 expression, fibrogenesis, and G2/M arrest of PTCs were determined. Results showed that HIF‐1α was upregulated in the kidneys of wild‐type (WT) AAN mice, accompanied by p21 upregulation, PTCs G2/M arrest and renal fibrosis, and these alterations were reversed in PT‐HIF‐1α‐KO AAN mice. Similar results were observed in HK‐2 cells and were further confirmed in primary PTCs from PT‐HIF‐1α‐KO and WT mice. Inhibiting p21 in HK‐2 cells and primary PTCs did not change the expression of HIF‐1α, but G2/M arrest and fibrogenesis were reduced. These data indicate that HIF‐1α plays a key role in renal fibrosis in AAN by inducing PTCs G2/M arrest modulated through p21. HIF‐1α may serve as a potential therapeutic target for AAN.